ArticleFrontiers in oncology2019
Identification of a Five-Pseudogene Signature for Predicting Survival and Its ceRNA Network in Glioma.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Establishment of a novel gene panel for prognosis assessment in patients with lower grade glioma.Medicine · 2026Article
- Stochastic LASSO for extremely high-dimensional genomic data.Scientific reports · 2026Article
- Identification of a ceRNA Network Regulating Malignant Transformation of Isocitrate Dehydrogenase Mutant Astrocytoma: An Integrated Bioinformatics Study.Current computer-aided drug design · 2025Article
- A prognostic binary classifier comprised of five critical mRNAs stratified pancreatic cancer patients following resection.Heliyon · 2024Article
- UBDP1 pseudogene and UBD network competitively bind miR‑6072 to promote glioma progression.International journal of oncology · 2024Article
- Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma.Apoptosis : an international journal on programmed cell death · 2024Article
- Fer-1 like family member 4 pseudogene: novel potential diagnostic and prognostic biomarker for cutaneous melanoma.EXCLI journal · 2024Article
- Impact of glioma metabolism-related gene ALPK1 on tumor immune heterogeneity and the regulation of the TGF-β pathway.Frontiers in immunology · 2024Article
- Identification ofBiomedicines · 2024Article
- The pseudogenes of eukaryotic translation elongation factors (EEFs): Role in cancer and other human diseases.Genes & diseases · 2022Review
- An Ensemble Deep Learning Model with a Gene Attention Mechanism for Estimating the Prognosis of Low-Grade Glioma.Biology · 2022Article
- Review
- Integrated analysis of competitive endogenous ribose nucleic acids (ceRNAs)-related regulatory networks in invasive and non-invasive non-functioning pituitary adenomas (NFPAs).Frontiers in surgery · 2022Article
- ANXA2P2: A Potential Immunological and Prognostic Signature in Ovarian Serous CystadenocarcinomaFrontiers in oncology · 2022Article
- N6-methyladenosine-associated prognostic pseudogenes contribute to predicting immunotherapy benefits and therapeutic agents in head and neck squamous cell carcinoma.Theranostics · 2022Article
- The World of Pseudogenes: New Diagnostic and Therapeutic Targets in Cancers or Still Mystery Molecules?Life (Basel, Switzerland) · 2021Review
- Glioblastoma and MiRNAs.Cancers · 2021Review
- The Role of the SOX9/lncRNA ANXA2P2/miR-361-3p/SOX9 Regulatory Loop in Cervical Cancer Cell Growth and Resistance to Cisplatin.Frontiers in oncology · 2021Article
- Promoting Prognostic Model Application: A Review Based on Gliomas.Journal of oncology · 2021Review
- Competing Endogenous RNA Networks in Glioma.Frontiers in genetics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.